549 related articles for article (PubMed ID: 28012402)
21. Identification of novel GCK and HNF1A/TCF1 mutations and polymorphisms in German families with maturity-onset diabetes of the young (MODY).
Toaima D; Näke A; Wendenburg J; Praedicow K; Rohayem J; Engel K; Galler A; Gahr M; Lee-Kirsch MA
Hum Mutat; 2005 May; 25(5):503-4. PubMed ID: 15841481
[TBL] [Abstract][Full Text] [Related]
22. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.
Thanabalasingham G; Pal A; Selwood MP; Dudley C; Fisher K; Bingley PJ; Ellard S; Farmer AJ; McCarthy MI; Owen KR
Diabetes Care; 2012 Jun; 35(6):1206-12. PubMed ID: 22432108
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.
Pihoker C; Gilliam LK; Ellard S; Dabelea D; Davis C; Dolan LM; Greenbaum CJ; Imperatore G; Lawrence JM; Marcovina SM; Mayer-Davis E; Rodriguez BL; Steck AK; Williams DE; Hattersley AT;
J Clin Endocrinol Metab; 2013 Oct; 98(10):4055-62. PubMed ID: 23771925
[TBL] [Abstract][Full Text] [Related]
24. GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY).
Cao H; Shorey S; Robinson J; Metzger DL; Stewart L; Cummings E; Hegele RA
Hum Mutat; 2002 Dec; 20(6):478-9. PubMed ID: 12442280
[TBL] [Abstract][Full Text] [Related]
25. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young.
Ellard S; Thomas K; Edghill EL; Owens M; Ambye L; Cropper J; Little J; Strachan M; Stride A; Ersoy B; Eiberg H; Pedersen O; Shepherd MH; Hansen T; Harries LW; Hattersley AT
Diabetologia; 2007 Nov; 50(11):2313-7. PubMed ID: 17828387
[TBL] [Abstract][Full Text] [Related]
26. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
[TBL] [Abstract][Full Text] [Related]
27. Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.
Szopa M; Matejko B; Ucieklak D; Uchman A; Hohendorff J; Mrozińska S; Głodzik W; Zapała B; Płatek T; Solecka I; Sani CM; Małecki MT
Endocrine; 2019 May; 64(2):246-253. PubMed ID: 30421137
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY).
McKinney JL; Cao H; Robinson JF; Metzger DL; Cummings E; Riddell DC; Sanderson SR; Pacaud D; Ho J; Hegele RA
Clin Invest Med; 2004 Jun; 27(3):135-41. PubMed ID: 15305805
[TBL] [Abstract][Full Text] [Related]
30. Frequency and characterization of mutations in genes in a large cohort of patients referred to MODY registry.
Breidbart E; Deng L; Lanzano P; Fan X; Guo J; Leibel RL; LeDuc CA; Chung WK
J Pediatr Endocrinol Metab; 2021 May; 34(5):633-638. PubMed ID: 33852230
[TBL] [Abstract][Full Text] [Related]
31. Maturity-onset diabetes of the young (MODY): an update.
Anık A; Çatlı G; Abacı A; Böber E
J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):251-63. PubMed ID: 25581748
[TBL] [Abstract][Full Text] [Related]
32. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
33. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
34. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed.
Stanik J; Dusatkova P; Cinek O; Valentinova L; Huckova M; Skopkova M; Dusatkova L; Stanikova D; Pura M; Klimes I; Lebl J; Gasperikova D; Pruhova S
Diabetologia; 2014 Mar; 57(3):480-4. PubMed ID: 24323243
[TBL] [Abstract][Full Text] [Related]
35. An Italian MODY family with proband and son carrying variants in GCK and HFN1A: is it a true case of digenic MODY?
Lucchesi D; Randazzo E; Del Prato S; Bianchi C
Acta Diabetol; 2024 Jan; 61(1):131-134. PubMed ID: 37730861
[TBL] [Abstract][Full Text] [Related]
36. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
[TBL] [Abstract][Full Text] [Related]
37. Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers.
Gloyn AL; Faber JH; Malmodin D; Thanabalasingham G; Lam F; Ueland PM; McCarthy MI; Owen KR; Baunsgaard D
PLoS One; 2012; 7(7):e40962. PubMed ID: 22859960
[TBL] [Abstract][Full Text] [Related]
38. Clinical and laboratory clues of maturity-onset diabetes of the young and determination of association with molecular diagnosis.
Karaoglan M; Nacarkahya G
J Diabetes; 2021 Feb; 13(2):154-163. PubMed ID: 32710514
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study).
Eide SA; Raeder H; Johansson S; Midthjell K; Søvik O; Njølstad PR; Molven A
Diabet Med; 2008 Jul; 25(7):775-81. PubMed ID: 18513305
[TBL] [Abstract][Full Text] [Related]
40. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
